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Abstract
An efficient synthesis of (−)-tetrahydrolipstatin (THL) is reported. This method takes advantage of
a phosphate tether-mediated, one-pot, sequential RCM/CM/hydrogenation protocol to deliver THL
in 8 total steps from a readily prepared (S,S)-triene. The strategy incorporates selective cross
metathesis, regio-selective hydrogenation, regio- and diastereoselective cuprate addition and
Mitsunobu inversion for installation of the C5 formamide ester subunit.
(−)-Tetrahydrolipstatin (THL, 1) is an anti-obesity drug marketed under generic name
Orlistat® and is a stable saturated form of the naturally occuring lipstatin (2) (Figure 1).
Lipstatin is a protein-reactive natural product and an irreversible pancreatic lipase inhibitor
which was first isolated in 1987 from Streptomyces toxytricini.1 The biological activity inherent
to this family of molecules is based on the reactivity of the β-lactone moiety which is readily
acylated by the pancreatic lipase enzyme. This process ultimately inhibits the enzyme reactivity
aimed at hydrolyzing triglycerides to produce free fatty acids which are then readily absorbed
into the dietary system.1b,2
Recently, the discovery of selective inhibition of thioesterase activity of fatty acid synthase
(FAS) in cancer cells has elevated the potential of Orlistat® as an anticancer drug.3,4 The
inhibition of FAS stops both endothelial cell proliferation and angiogenesis and ultimately
delays tumor progression in a variety of cancer cells. This promising activity highlights the
broad and interesting biological profile of Orlistat® and has prompted renewed synthetic efforts
and corresponding biology of THL, lipstatin and analogs thereof.4,5 Herein we report a concise
total synthesis of (−)-tetrahydrolipstatin via a strategy utilizing a phosphate-tether-mediated,
one-pot, sequential RCM/CM/hydrogenation pathway of triene (S,S)-7.6 Overall, the reported
phanson@ku.edu.
Supporting Information Available Experimental details and spectroscopic data of new compounds. This material is available free of
charge via the Internet at http://pubs.acs.org.
NIH Public Access
Author Manuscript
Org Lett. Author manuscript; available in PMC 2011 April 2.
Published in final edited form as:













synthetic route comprises 9 total steps from the readily prepared diene diol-(S,S)-8 and
highlights the utility of phosphate tethered processes and one-pot, multi-step operations.
The first total synthesis of THL was achieved in 1987 by Schneider and coworkers utilizing
Wittig olefination and an aldol condensation as key steps in a non-stereoselective process.7
Numerous total syntheses,8 formal syntheses9 and synthetic analogues have followed this
initial report, with the majority of synthetic pathways comprised of 14–25 steps. The shortest
routes to THL reported to-date range from 10–12 steps using an array of synthetic strategies,
including, (i) a 12-step anti-aldol approach,8i (ii) a 12-step diastereoselective allylation and
crotylation sequence utilizing allyl/crotyltrifluoroborates,8n (iii) a 10-step tandem
Mukaiyama-aldol lactonization,8o and (iv) a 12-step Prins cyclization approach.8q Other
noteworthy strategies include substrate-controlled stereoselective hydrogenation to install the
C2-C3 stereocenters,7c Lewis acid-catalyzed [2+2] cycloaddition,8f anti-aldol approach,8h
substrate-controlled [2+3] cycloaddition,8j and diastereoselective aldol reaction with an
embedded iron chiral auxiliary.8t
The route reported herein is highlighted in the retrosynthetic analysis shown in Scheme 1. THL
(1) can be readily derived from β-lactone intermediate 3 via simple silyl deprotection and
Mitsunobu esterification.7a β-Lactone 3 in turn can be synthesized from diol 4 via a 3-step
sequence of TIPS-protection, ozonolysis/oxidation and lactonization. Diol 4 is obtained from
5 via diastereo-selective cuprate addition and phosphate tether removal under reductive
conditions. Bicyclic phosphate 5 is in turn derived from (S,S,PS)-6 via cross-metathesis and
regioselective hydrogenation. The bicyclic phosphate, (S,S,PS)-6,10 can be produced in a
straightforward 2-step sequence from desymmetrization of the pseudo-C2-symmetric triene
(S,S)-7 using an RCM/phosphate tether method inspired by Burke and coworkers.11 Triene
(S,S)-7 is readily prepared from the C2-symmetric anti-diene diol (S,S)-812 in one step using
phosphoramidite chemistry. Optimization was envisioned for a one-pot, sequential RCM/CM/
hydrogenation sequence that would access 5 directly from triene (S,S)-7.
Initially, a linear approach was followed for the synthesis of 5 from bicyclic phosphate
(S,S,PS)-6,13,14 which was synthesized via RCM desymmetrization of triene (S,S)-7 using
[(IMesH2)(PCy3)(Cl)2Ru=CHPh; cat-B]15 (Scheme 2). Cross metathesis of phosphate
(S,S,PS)-6 and 1-undecene, a type I olefin,16 using cat-C17 gave desired product 9 with > 99:1
E:Z selectivity. Regioselective hydrogenation of the exo-cyclic olefin under mild conditions
(o-nitrobenzenesulfonyl hydrazine (o-NBSH), Et3N, CH2Cl2)18 via an in situ generated
diimide afforded desired product 5 in 85% yield.10b
The development of a one-pot, RCM/CM/hydrogenation sequence was next investigated
(Schemes 3 and 4). Recently a number of tandem and sequential protocols involving metathesis
have followed the seminal report by Grubbs and coworkers.19 Initially, a one-pot, sequential
CM/hydrogenation procedure was investigated using CH2Cl2 as a common solvent with no
workup after the metathesis event. This CM/hydrogenation sequence proceeded smoothly
yielding the desired hydrogenated product 5 in 53% yield with an average of 73% yield for
each step (Scheme 3).
To further streamline the process, we optimized the previously reported two-step protocol for
synthesizing triene 7 from the corresponding diene-diol 86a using a one-step process employing
allyl tetraisopropylphosphoro-diamidite in the presence of tetrazole, followed by oxidation
with m-CPBA. This method provided the desired triene 7 in 64% yield (Scheme 4).20 An RCM/
CM/hydrogenation sequence from triene 7 was next investigated. Starting with triene (S,S)-7,
5 RCM in the presence of cat-B and subsequent CM with cat-C, followed by hydrogenation
with o-NBSH, gave the desired hydrogenated product 5 in 40% yield along with 7% of the
hydrogenated product of unreacted (S,S,PS)-6 phosphate [5:1 ratio].21 Overall, this method
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represents an average yield of 74% for each step. Moreover, it simplifies the synthesis of 5 to
a 2-step protocol from diene-diol (S,S)-8.
With 5 in place, 7-steps were required to complete the total synthesis of THL (1) (Scheme 5).
SN2′ addition on endo-cyclic olefin with in situ generated organocuprate reagent followed by
methylation with TMSCHN2 proceeds with high regio- and diastereoselectivity giving desired
monocyclic phosphate 10.6 The phosphate tether was next removed under reductive conditions
with the use of two equivalents of LiAlH4 affording diol 4 with all the desired stereocenters
that are carried through until the last step of the sequence where inversion of the C5 stereocenter
is carried out with Mitsunobu esterification. Selective silyl protection of the sterically more
accessable C5 alcohol in 4 gave the desired silylether adduct 11 in 80% yield.22 Conversion
to carboxylic acid 12 was accomplished via ozonolysis/Pinnick oxidation protocol affording
12 in an overall 93% yield. The TIPS-protected β-lactone 3 was next readily accessed via
lactonization of β-hydroxy carboxylic acid 12 in the presence of BOPCl through a mixed
anhydride intermediate. Ensuing TIPS-deprotection under mild basic conditions (HF·pyr)
followed by esterification with N-formyl-L-leucine under Mitsunobu inversion conditions
(DIAD, PPh3) developed by Schneider7a afforded the desired final product tetrahydrolipstatin
(1) in 94% yield with all matching characterization of the reported data.7
In conclusion, a successful synthesis of (−)-tetrahydrolipstatin has been developed that
incorporates a phosphate tether approach starting from diene-diol (S,S)-8. Overall, a 9-step
route from diene-diol (S,S)-8 employing a phosphorodiamidite coupling and one-pot,
sequential RCM/CM/hydrogenation sequence has been developed. Current efforts are focused
on further optimization of the aforementioned one-pot, sequential RCM/CM/hydrogenation
process, phosphorodiamidite coupling as well as additional phosphate tether approaches
towards bioactive natural products containing 1,3-anti-diol subunits. The use of this one-pot,
sequential RCM/CM/-hydrogenation sequence towards the synthesis of other bioactive natural
products is ongoing and will be reported in due course.
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Retrosynthetic Analysis of (−)-Tetrahydrolipstatin
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Stepwise RCM, CM and hydrogenation sequence
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One-pot, Sequential CM/Hydrogenation Pathway
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Phosphorodiamidite coupling and One-Pot, Sequential RCM/CM/Hydrogenation Sequence.
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Total Synthesis of (−)-Tetrahydrolipstatin (1)
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